Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.

Edoardo Bruno VicenziElisabetta CaloreNunzia DecembrinoMassimo BergerKatia PerruccioFrancesca CarraroSara RossinMaria Caterina PuttiMariadelfina MolinaroGloria TridelloSimone Cesaro

Published in: European journal of haematology (2018)

Posaconazole may be a valuable antifungal agent in children despite the incomplete knowledge of its pharmacokinetic characteristics.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
healthcare
young adults
peritoneal dialysis
patient reported outcomes